IL2 and metastatic melanoma: The PIVOT-02 study (NCT02983045) exhibited the safety and efficacy of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, plus nivolumab in the first-line treatment of metastatic melanoma.